NeuroMetrix (NASDAQ:NURO) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report released on Thursday morning. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Performance

NURO opened at $3.65 on Thursday. NeuroMetrix has a 1 year low of $2.70 and a 1 year high of $11.82. The stock’s 50 day simple moving average is $3.75 and its 200-day simple moving average is $3.82.

NeuroMetrix (NASDAQ:NURO) last released its quarterly earnings data on Thursday, February 22nd. The medical device company reported ($1.43) EPS for the quarter. NeuroMetrix had a negative return on equity of 31.31% and a negative net margin of 110.64%. The business had revenue of $1.32 million for the quarter.

Hedge Funds Weigh In On NeuroMetrix

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Northern Trust Corp acquired a new position in NeuroMetrix during the second quarter worth $41,000. Virtu Financial LLC bought a new position in NeuroMetrix during the 4th quarter valued at about $43,000. Millennium Management LLC boosted its position in NeuroMetrix by 102.3% in the fourth quarter. Millennium Management LLC now owns 20,530 shares of the medical device company’s stock valued at $30,000 after buying an additional 10,384 shares in the last quarter. Cerity Partners LLC bought a new stake in NeuroMetrix during the fourth quarter worth about $108,000. Finally, Citadel Advisors LLC increased its holdings in shares of NeuroMetrix by 44.3% during the third quarter. Citadel Advisors LLC now owns 34,699 shares of the medical device company’s stock worth $97,000 after buying an additional 10,652 shares in the last quarter. Institutional investors own 19.40% of the company’s stock.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies.